CERS News and Press, Cerus Corporation From 08/29/20

Investors in convalescent plasma players have experienced a bit of volatility of late related to the FDA emergency use nod to treat COVID-19 patients. More news on: Kamada Ltd., Grifols, S.A., XBiotech Inc., Healthcare stocks news, Read more ...

Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +67%  on FDA nod for convalescent plasma. More news on: Sonnet BioTherapeutics Holdings, Inc., Liminal BioSciences Inc., ADMA Biologics, Inc., Stocks on the move, , Read more ...

"On the therapeutics front...in our battle against the China virus that will save countless lives, the FDA has issued an emergency use authorization — and that's such powerful term, emergency use authorization — for a treatment known as convalescent plasma," President Trump s...

Processors of antibody-rich convalescent plasma, derived from COVID-19 patients who have recovered from the infection, are under the gun on a delay of the expected emergency use authorization from the FDA for the treatment of COVID-19. More news on: Kamada Ltd., Grifols, S.A., XBiotech I...

The biotech industry has been on a tear as the search for coronavirus treatments heat up. Here are four biotech stocks that analysts love: Compugen (CGEN), Cerus (CERS), Mersana Therapeutics (MRSN) and Protagonist Therapeutics (PTGX). Wall Street analysts keep a close eye on price movement,...

Results from a large-scale study involving more than 35K severely ill COVID-19 patients demonstrated that the early administration of convalescent plasma, derived from patients who recovered from the infection and who generated antibodies against SARS-CoV-2, lowered the mortality rate. ...

Cerus ( CERS ) has announced that its INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5M treatable platelet and plasma doses, since commercial launch in early 2015. More news on: Cerus Corporation, Healthcare stocks news, Read more ...

Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch. “This is a significant milestone for Cerus and highlights the scope our technology ...

Image source: The Motley Fool. Cerus Corporation   (NASDAQ: CERS) Q2 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading

Cerus Corporation (CERS) Q2 2020 Results Earnings Conference Call August 04, 2020, 04:30 PM ET Company Participants Tim Lee - Investor Relations Nina Mufti - Vice President, Development Obi Greenman - President and Chief Executive Officer Kevin Green - Chief Financial Officer ...